Sugi Predict

Sugi Predict / Compounds / SCHEMBL1960915

SCHEMBL1960915

SCHEMBL1960915

CCCCCCCCCC[C@H](N)C(=O)O

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRIK1 P39086 2/20 0.69
▸ GRIK2 Q13002 2/20 0.69
▸ SLC1A2 P43004 2/20 0.66
▸ SLC1A1 P43005 2/20 0.66
▸ GSR P00390 1/20 0.61
▸ GPR84 Q9NQS5 3/20 0.59
▸ FFAR1 O14842 1/20 0.59
▸ MAPT P10636 1/20 0.57
▸ LCK P06239 1/20 0.57
▸ PPARD Q03181 1/20 0.57
▸ ZDHHC20 Q5W0Z9 1/20 0.57
▸ ZDHHC2 Q9UIJ5 1/20 0.57
▸ NOD1 Q9Y239 2/20 0.57
▸ SLC1A3 P43003 1/20 0.57
▸ NOS2 P35228 2/20 0.56
▸ DDAH1 O94760 1/20 0.56
▸ ARG2 P78540 4/20 0.55
▸ ARG1 P05089 3/20 0.55
▸ ACE2 Q9BYF1 1/20 0.53
▸ NOS3 P29474 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7889574 1.00 GRIK1 (0.69) GRIK1GRIK2SLC1A2SLC1A1GSR
SCHEMBL7878467 1.00 GRIK1 (0.69) GRIK1GRIK2SLC1A2SLC1A1GSR
SCHEMBL660684 1.00 GRIK1 (0.69) GRIK1GRIK2SLC1A2SLC1A1GSR
SCHEMBL3689310 1.00 GRIK1 (0.69) GRIK1GRIK2SLC1A2SLC1A1GSR
SCHEMBL1527353 1.00 GRIK1 (0.69) GRIK1GRIK2SLC1A2SLC1A1GSR
SCHEMBL1738925 1.00 GRIK1 (0.69) GRIK1GRIK2SLC1A2SLC1A1GSR
SCHEMBL23531056 1.00 GRIK1 (0.69) GRIK1GRIK2SLC1A2SLC1A1GSR
SCHEMBL5048329 1.00 GRIK1 (0.69) GRIK1GRIK2SLC1A2SLC1A1GSR
SCHEMBL7861411 1.00 GRIK1 (0.69) GRIK1GRIK2SLC1A2SLC1A1GSR
SCHEMBL10579474 1.00 GRIK1 (0.69) GRIK1GRIK2SLC1A2SLC1A1GSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260103488-A1 ACTIVATING AGENTS INTERK PEPTIDE THERAPEUTICS LIMITED (AU) 2026-04-16 — — US disclosed
WO-2025070720-A1 PEPTIDE ペプチドリーム株式会社 2025-04-03 — — WO disclosed
WO-2025070731-A1 PEPTIDEPEPTIDE ペプチドリーム株式会社 2025-04-03 — — WO disclosed
US-20250019397-A1 Peptide Activating Agent INTERK PEPTIDE THERAPEUTICS LIMITED (AU) 2025-01-16 — — US disclosed
US-12134663-B2 Cationic peptides for activating Lck INTERK PEPTIDE THERAPEUTICS LIMITED (AU) 2024-11-05 — — US disclosed
US-11912789-B2 Peptide activating agent INTERK PEPTIDE THERAPEUTICS LIMITED (AU) 2024-02-27 — — US disclosed
US-20230172886-A1 (S)-2-AMINO-6-((3-AMINOPROPYL)AMINO)HEXANOIC ACID (APL) FOR USE IN THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS (NASH), LIVER INFLAMMATION, HEPATOCELLULAR BALLOONING, LIVER FIBROSIS AND STEATOSIS TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2023-06-08 — — US disclosed
US-20210380639-A1 Activating Agents INTERK PEPTIDE THERAPEUTICS LIMITED (AU) 2021-12-09 — — US disclosed
US-20210214391-A1 Peptide Activating Agent INTERK PEPTIDE THERAPEUTICS LIMITED (AU) 2021-07-15 — — US disclosed
EP-3794014-A1 PEPTIDE ACTIVATING AGENT InterK Peptide Therapeutics Limited (AU) 2021-03-24 — — EP disclosed
EP-3794015-A1 ACTIVATING AGENTS InterK Peptide Therapeutics Limited (AU) 2021-03-24 — — EP disclosed
CN-112399970-A Peptide activators 英特肽治疗有限公司 2021-02-23 — — CN disclosed
CN-112368293-A Activating agent 英特肽治疗有限公司 2021-02-12 — — CN disclosed
WO-2019218016-A1 PEPTIDE ACTIVATING AGENT INTERK PEPTIDE THERAPEUTICS LIMITED (AU) 2019-11-21 — — WO disclosed
WO-2019218015-A1 ACTIVATING AGENTS INTERK PEPTIDE THERAPEUTICS LIMITED (AU) 2019-11-21 — — WO disclosed
US-8716242-B2 β-hairpin peptidomimetics POLYPHOR AG (CH) 2014-05-06 — — US disclosed
US-20120283196-A1 BETA-HAIRPIN PEPTIDOMIMETICS POLYPHOR AG (CH) 2012-11-08 — — US disclosed
WO-2011066869-A1 BETA-HAIRPIN PEPTIDOMIMETICS POLYPHOR AG (CH) 2011-06-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250019397-A1 Peptide Activating Agent LCK, CD69, VIP GRIK1 1778/4885GRIK2 2281/4885SLC1A2 4349/4885
US-12134663-B2 Cationic peptides for activating Lck LCK, CD69, NFATC1 GRIK1 1716/4885GRIK2 2064/4885SLC1A2 3387/4885
US-20120283196-A1 BETA-HAIRPIN PEPTIDOMIMETICS CXCL12, CXCR4, CXCR1 GRIK1 4195/4885GRIK2 4575/4885SLC1A2 1854/4885
US-20210214391-A1 Peptide Activating Agent LCK, CD69, VIP GRIK1 1778/4885GRIK2 2281/4885SLC1A2 4349/4885
US-20230172886-A1 (S)-2-AMINO-6-((3-AMINOPROPYL)AMINO)HEXANOIC ACID (APL) FOR USE IN THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS (NASH), LIVER INFLAMMATION, HEPATOCELLULAR BALLOONING, LIVER FIBROSIS AND STEATOSIS FABP1, AADAT, FABP6 GRIK1 1131/4885GRIK2 932/4885SLC1A2 175/4885
US-11912789-B2 Peptide activating agent LCK, CD69, VIP GRIK1 1778/4885GRIK2 2281/4885SLC1A2 4349/4885
US-20260103488-A1 ACTIVATING AGENTS LCK, LTK, CD14 GRIK1 1911/4885GRIK2 895/4885SLC1A2 2912/4885
US-20210380639-A1 Activating Agents LCK, CD69, NFATC1 GRIK1 1292/4885GRIK2 1454/4885SLC1A2 4428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback